Human organic cation transporter 1 (OCT1)

Human organic cation transporter 1 (OCT1; SLC22A1) is a polyspecific membrane transporter primarily expressed on the sinusoidal (basolateral) membrane of hepatocytes, with minor expression in other tissues such as the intestine and kidney[5][7][3]. OCT1 mediates the uptake of structurally diverse endogenous and exogenous organic cations, including drugs like metformin, morphine, oxaliplatin, and thiamine, thereby profoundly influencing their hepatic metabolism, efficacy, and safety[1][3][5][7]. As a member of the solute carrier family 22 (SLC22), OCT1 belongs to the major facilitator superfamily and exhibits a characteristic 12-transmembrane domain architecture with an extended extracellular domain unique to the protein[2][3][6]. The transport mechanism is bidirectional and does not depend on sodium or pH, functioning via facilitated diffusion in accordance with substrate electrochemical gradients[7]. Because of its broad substrate profile and the clinical significance of its polymorphisms, OCT1 is an essential determinant in pharmacogenetics and drug development, particularly as a major determinant of metformin pharmacokinetics and efficacy in the treatment of type 2 diabetes[5][3]. It is also implicated in drug-induced liver injury, chemotherapeutic drug resistance, and the hepatic handling of endogenous metabolites. Safety and therapeutic outcomes can be substantially affected by genetic variants, inhibition by co-administered compounds, and regulatory mechanisms at the cellular level.

Other names

SLC22A1hOCT1

Substrate for cellular uptake (e.g., metformin is transported into hepatocytes by OCT1); Competitive inhibition (e.g., spironolactone blocks OCT1-mediated substrate transport); Polyspecific bidirectional transport of endogenous and exogenous organic cations through facilitated diffusion (Na+- and pH-independent; follows electrochemical gradients)